NCT06093672 2026-01-27
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
Clinical Trials
8 trialsNCT01761968 2025-04-30
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
Phase 2 Active not recruiting
NCT00792506 2022-02-02
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Italfarmaco
Phase 2 Terminated
NCT00496431 2022-01-27
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Italfarmaco
Phase 1/2 Terminated
NCT00792467 2021-05-11
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Italfarmaco
Phase 1/2 Completed
NCT00606307 2019-12-03
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Italfarmaco
Phase 2 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT01901432 2019-07-30
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Italfarmaco
Phase 1/2 Completed